Guidance on the treatment of amblyopia has benefited substantially from outcomes obtained from randomized clinical trials (RCTs). Most RCTs on amblyopia treatment have been conducted by the National Eye Institute–supported Pediatric Eye Disease Investigator Group (PEDIG). The PEDIG public website1 shows the breadth of amblyopia research reported by that group and provides a key resource not only for guiding amblyopia eye care professionals, but also for instructing the design, conduct, and interpretation of contemporary clinical research on amblyopia treatment.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Musch DC, Baker JD. Patching and Atropine for Severe Amblyopia: Are Both Better Than Patching Alone? JAMA Ophthalmol. Published online July 15, 2021. doi:10.1001/jamaophthalmol.2021.2425
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: